reports
Total number of shares and voting rights in Zealand Pharma as of Septe...
Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end o...
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporat...
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Rachel James-Owens as Vice President, Corporate Communications & Media Relations. Rachel brings over 20 years of global...
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
Novartis AG: 1 director
A director at Novartis AG sold 2,600 shares at 97.158CHF and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 20 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 20,924 divided into 20,924 new shares ...
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on...
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity. “Obesity is one of ...
- Martin Marandon-Carlhian
- Oliver Metzger
- Sinan Doganli
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
KPN ROYAL KPN NV
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
NOVN NOVARTIS AG
EVT EVOTEC SE
EN BOUYGUES SA
HNR1 HANNOVER RUECK SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
ELG ELMOS SEMICONDUCTOR SE
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
IMPN IMPLENIA AG
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
FNTN FREENET AG
AZN ASTRAZENECA PLC
BIM BIOMERIEUX SA
DUE DURR AG
BFSA BEFESA SA
SANT S&T AG
AEIN ALLGEIER HOLDING AG
HAG HENSOLDT AG
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
- Martin Marandon-Carlhian
- Oliver Metzger
- Sinan Doganli
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
KPN ROYAL KPN NV
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
NOVN NOVARTIS AG
EVT EVOTEC SE
EN BOUYGUES SA
HNR1 HANNOVER RUECK SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
ELG ELMOS SEMICONDUCTOR SE
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
IMPN IMPLENIA AG
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
FNTN FREENET AG
AZN ASTRAZENECA PLC
BIM BIOMERIEUX SA
DUE DURR AG
BFSA BEFESA SA
SANT S&T AG
AEIN ALLGEIER HOLDING AG
HAG HENSOLDT AG
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
- Team Pharma
- Team Pharma
Zealand Pharma to participate in upcoming investor conferences in Sept...
Zealand Pharma to participate in upcoming investor conferences in September 2025 Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investo...
Zealand Pharma major shareholder announcement: Van Herk Investments B....
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Du...
- Jacob Mekhael
Zealand Pharma 2Q25 results confirm timelines, upcoming CMD in Decembe...
Zealand's 2Q25 results hold no surprises, and show that the company is on track operationally with pipeline timelines being reiterated. While no big data readouts are expected for the remainder of the year, the company is gearing up for a news heavy 1H26 and we most look forward to phase 2b results with petrelintide (amylin analog, partnered with Roche). Zealand reported a cash position of DKK 16,578m, and expects an additional $ 250m in anniversary payments under the Roche agreement in addition...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
Zealand Pharma Announces Financial Results for the First Half of 2025
Zealand Pharma Announces Financial Results for the First Half of 2025 Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche’s Pharma Day in Septe...
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to pre...
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financia...
Zealand Pharma major shareholder announcement: Van Herk Investments B....
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch re...
- Konrad Zomer
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
REL RELX PLC
HEIA HEINEKEN NV
PUB PUBLICIS GROUPE SA
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
DGE DIAGEO PLC
APAML APERAM SA
VOLV B VOLVO AB CLASS B
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
ABB ABB LTD.
LSEG LONDON STOCK EXCHANGE GROUP PLC
SZG SALZGITTER AG
AMUN AMUNDI SA
WKL WOLTERS KLUWER NV
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
EZJ EASYJET PLC
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
ASSA B ASSA ABLOY AB CLASS B
YPSN YPSOMED HOLDING AG
CFR COMPAGNIE FINANCIERE RICHEMONT SA
RIO RIO TINTO PLC
BHP BHP GROUP LTD
ASML ASML HOLDING NV
AMAG AMAG AUSTRIA METALL AG
VUL VULCAN ENERGY RESOURCES
FER FERROVIAL SA
PUIG PUIG BRANDS
AAL ANGLO AMERICAN PLC
- Konrad Zomer
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
REL RELX PLC
HEIA HEINEKEN NV
PUB PUBLICIS GROUPE SA
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
DGE DIAGEO PLC
APAML APERAM SA
VOLV B VOLVO AB CLASS B
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
NOVN NOVARTIS AG
ABB ABB LTD.
LSEG LONDON STOCK EXCHANGE GROUP PLC
SZG SALZGITTER AG
AMUN AMUNDI SA
WKL WOLTERS KLUWER NV
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
EZJ EASYJET PLC
NDA AURUBIS AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
ASSA B ASSA ABLOY AB CLASS B
YPSN YPSOMED HOLDING AG
CFR COMPAGNIE FINANCIERE RICHEMONT SA
RIO RIO TINTO PLC
BHP BHP GROUP LTD
ASML ASML HOLDING NV
AMAG AMAG AUSTRIA METALL AG
VUL VULCAN ENERGY RESOURCES
FER FERROVIAL SA
PUIG PUIG BRANDS
AAL ANGLO AMERICAN PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.